We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+17.98%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.89B
AUM Growth
+$155M
Cap. Flow
-$17.4M
Cap. Flow %
-0.92%
Top 10 Hldgs %
59.01%
Holding
53
New
4
Increased
8
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
BIOA
BioAge Labs
BIOA
+$32.7M
2
RNAM
Avidity Biosciences
RNAM
+$27.1M
3
CRBP icon
Corbus Pharmaceuticals
CRBP
+$17.9M
4
MBX
MBX Biosciences
MBX
+$16M
5
ANAB icon
AnaptysBio
ANAB
+$11.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$19.8M
2
CGEM icon
Cullinan Oncology
CGEM
+$19.6M
3
ACLX
Arcellx
ACLX
+$18.3M
4
BHVN icon
Biohaven
BHVN
+$15.6M
5
INSM icon
Insmed
INSM
+$12.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRGX
26
DELISTED
CARGO Therapeutics
CRGX
$21.8M 1.16%
1,182,563
– –
ARQT icon
27
Arcutis Biotherapeutics
ARQT
$3.18B
$21.6M 1.15%
2,325,000
-200,000
-8% -$1.97M
RYTM icon
28
Rhythm Pharmaceuticals
RYTM
$7.96B
$21M 1.11%
400,000
-75,000
-16% -$3.59M
BHVN icon
29
Biohaven
BHVN
$2.21B
$20.1M 1.07%
401,963
-400,000
-50% -$15.6M
URGN icon
30
UroGen Pharma
URGN
$2.29B
$19.7M 1.04%
1,550,000
-100,000
-6% -$1.48M
YMAB
31
DELISTED
Y-mAbs Therapeutics
YMAB
$19.1M 1.01%
1,450,000
– –
MBX
32
MBX Biosciences
MBX
$3.23B
$18.2M 0.96%
+700,000
New +$16M
TARS icon
33
Tarsus Pharmaceuticals
TARS
$2.84B
$16.4M 0.87%
500,000
– –
AVBP icon
34
ArriVent BioPharma
AVBP
$1.44B
$13.8M 0.73%
585,462
+70,462
+14% +$1.6M
ANAB icon
35
AnaptysBio
ANAB
$1.68B
$11.5M 0.61%
+342,465
New +$11.7M
KRRO icon
36
Korro Bio
KRRO
$195M
$8.88M 0.47%
265,826
– –
SLN
37
Silence Therapeutics
SLN
$564M
$7.27M 0.39%
400,000
-225,000
-36% -$4.19M
ENGN icon
38
enGene Therapeutics
ENGN
$121M
$6.6M 0.35%
1,000,000
– –
STOK icon
39
Stoke Therapeutics
STOK
$2.11B
$5.25M 0.28%
427,163
– –
NGNE icon
40
Neurogene
NGNE
$712M
$4.5M 0.24%
107,344
– –
GHRS icon
41
GH Research
GHRS
$2.08B
$3.97M 0.21%
593,043
– –
YARW
42
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$2.62M 0.14%
27,887
– –
VERV
43
DELISTED
Verve Therapeutics
VERV
$1.69M 0.09%
350,000
– –
ARTV
44
Artiva Biotherapeutics
ARTV
$551M
$1.6M 0.08%
+103,633
New +$1.2M
RAPT
45
DELISTED
RAPT Therapeutics
RAPT
$998K 0.05%
62,094
– –
CGEM icon
46
Cullinan Oncology
CGEM
$1.14B
– –
-1,125,000
Closed -$19.6M
CMPX icon
47
Compass Therapeutics
CMPX
$387M
– –
-2,030,823
Closed -$2.03M
IBRX icon
48
PUT
ImmunityBio
IBRX
$8.1B
– –
-1,250,000
Closed -$7.9M
IDYA icon
49
IDEAYA Biosciences
IDYA
$3.56B
– –
-245,000
Closed -$8.6M
LNTH icon
50
Lantheus
LNTH
$6.59B
– –
-75,000
Closed -$6.02M
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Cormorant Asset Management held 53 positions worth $1.89B, up 8.9% from $1.73B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management's Q3 2024 filing shows 4 new, 8 increased, 11 reduced and 8 closed positions. Its largest new stake was BioAge Labs: 1,629,529 shares worth $33.9M. The largest sale was Sarepta Therapeutics, an estimated $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Cormorant Asset Management's largest Q3 2024 buy was BioAge Labs: 1,629,529 shares worth $33.9M.
  • Cormorant Asset Management added most to Avidity Biosciences in Q3 2024, an estimated $27.1M increase.
  • Cormorant Asset Management's biggest Q3 2024 reduction was Arcellx, cutting an estimated $18.3M.
  • Cormorant Asset Management fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $19.8M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.89B portfolio in Q3 2024.
  • Cormorant Asset Management opened 4 new positions and closed 8 in Q3 2024.
  • Cormorant Asset Management's portfolio value rose 8.9% quarter-over-quarter to $1.89B.

Based on Cormorant Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.